{
    "clinical_study": {
        "@rank": "159877", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in\n      preventing Cytmegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from\n      eligible patients will be collected for the 6 months following transplantation."
        }, 
        "brief_title": "An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Cytomegalovirus Infections", 
        "condition_browse": {
            "mesh_term": "Cytomegalovirus Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Liver transplant recipients, >/= 16 years of age\n\n          -  Transplantation between January 2004 and June 2009\n\n          -  CMV seronegative recipient (R-) who received a liver transplant from a seropositive\n             donor (D+)\n\n          -  Valganciclovir therapy for at least 70 days beginning within 10 days post\n             transplantation\n\n          -  Assessment of CMV disease status within the first 6 months post transplantation\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Liver transplant recipients at high risk of developing Cytomegalovirus disease"
            }
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062294", 
            "org_study_id": "ML25224"
        }, 
        "intervention_browse": {
            "mesh_term": "Valganciclovir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "3010"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gen\u00e8ve", 
                        "country": "Switzerland", 
                        "zip": "1211"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Z\u00fcrich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients developing Cytomegalovirus (CMV) disease within 6 months of liver transplantation under Valcyte prophylaxis", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062294"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}